1-(1,3-苯并噻唑-2-基)-2-溴-1-乙酮 | 54223-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 1-(1,3-苯并噻唑-2-基)-2-溴-1-乙酮
• 中文别名: 2-(2-溴乙酰基)苯并噻唑；1-(1,3-苯并噻唑)-2-溴-1-乙酮
• 英文名称: 1-(benzo[d]thiazol-2-yl)-2-bromoethanone
• 英文别名: 1-(benzothiazol-2-yl)-2-bromoethanone；2-(bromoacetyl)benzothiazole；1-(benzo[d]thiazol-2-yl)-2-bromoethan-1-one；1-(1,3-Benzothiazol-2-yl)-2-bromo-1-ethanone；1-(1,3-benzothiazol-2-yl)-2-bromoethanone
• CAS: 54223-20-0
• 化学式: C₉H₆BrNOS
• mdl: MFCD03659698
• 分子量: 256.123
• InChiKey: AYWGYNKWZWBMSV-UHFFFAOYSA-N

物化性质

• 熔点：
  86-87 ºC
• 沸点：
  347.7±44.0 °C(Predicted)
• 密度：
  1.696±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 危险类别码：
  R34
• 海关编码：
  2934200090
• 安全说明：
  S26,S36/37/39,S45
• 储存条件：
  2-8°C

SDS

Name:	1-(1 3-Benzothiazol-2-yl)-2-bromo-1-ethanone 90+% Material Safety Data Sheet
Synonym:
CAS:	54223-20-0

Section 1 - Chemical Product MSDS Name:1-(1 3-Benzothiazol-2-yl)-2-bromo-1-ethanone 90+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
54223-20-0	1-(1,3-Benzothiazol-2-yl)-2-bromo-1-et	90+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 54223-20-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 85 - 87 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H6BrNOS
Molecular Weight: 256.12

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 54223-20-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(1,3-Benzothiazol-2-yl)-2-bromo-1-ethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 54223-20-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 54223-20-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 54223-20-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(1,3-苯并噻唑-2-基)-2-溴-1-乙酮 以 乙醇 、 溶剂黄146 为溶剂， 反应 5.58h， 生成 4-(2'-benzothiazolyl)-2-ethylmercapto-1-phenylimidazole
  参考文献：
  名称：

  Sawhney, S. N.; Kodali, D. R.; Dhindsa, G. S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 6, p. 584 - 589

  摘要：

  DOI：
• 作为产物：
  描述：

  alpha-甲基-(7ci,8ci,9ci)-2-苯并噻唑甲醇 在 manganese(IV) oxide 、 copper(ll) bromide 作用下， 以 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 12.0h， 生成 1-(1,3-苯并噻唑-2-基)-2-溴-1-乙酮
  参考文献：
  名称：

  热激蛋白70（Hsp70）抑制剂JG-98的中性类似物。

  摘要：

  分子伴侣的热激蛋白70（Hsp70）家族在肿瘤中高表达。含有吡啶鎓修饰的苯并噻唑的抑制剂（例如JG-98）与Hsp70中一个保守的变构位点结合，在癌细胞中显示出有希望的抗增殖活性。当与Hsp70结合时，带电的吡啶鎓会形成良好的接触。然而，该部分也增加了抑制剂的荧光，在生化和基于细胞的测定中引起了不希望的干扰。在这里，我们探讨了吡啶鎓是否可以被中性吡啶取代。我们报道吡啶修饰的苯并噻唑，例如化合物17h（JG2-38），具有降低的荧光，但在乳腺癌和前列腺癌细胞系中仍保留有希望的抗增殖活性（EC50值〜0.1至0.07 µM）。

  DOI：

  10.1016/j.bmcl.2020.126954

文献信息

• POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：DE PERETTI Danielle

  公开号：US20110065727A1

  公开（公告）日：2011-03-17

  Compounds of formula (I): wherein R, R 1 , R 2 , R 3 , R 4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

  式（I）的化合物： 其中R、R1、R2、R3、R4和X如披露中所定义，或其酸盐，以及其治疗用途和合成过程。
• CONVENIENT SYNTHESIS OF SOME NEW 1,3,4-THIADIAZOLE AND 1,3,4-SELENADIAZOLE DERIVATIVES
  作者：Ahmad M. Farag、Kamal M. Dawood、Zaghloul E. Kandeel

  DOI：10.1080/10426509708033695

  日期：1997.11

  Abstract The novel 1-aryl-5-(benzothiazol-2-yl)carbonyl-2-imino-1,3,4-thiadiazoles 7a-c and their selenium analogues 8a-c were prepared in high yields by coupling of 2-thiocyanatoacetylbenzothiazole 3 or its selenium analogue 4 with aromatic diazonium salts. The same products were alternatively obtained from the reaction of the hydrazonoyl bromides 2a-c with potassium thiocyanate and with potassium

  摘要 通过偶联 2-硫氰基乙酰苯并噻唑，以高收率制备了新型 1-芳基-5-(苯并噻唑-2-基)羰基-2-亚氨基-1,3,4-噻二唑 7a-c 及其硒类似物 8a-c。 3 或其硒类似物 4 与芳香重氮盐。相同的产物分别由腙酰溴化物 2a-c 与硫氰酸钾和硒氰酸钾的反应获得。7a-c 和 8a-c 与乙酸酐和苯甲酰氯的反应分别得到相应的 N-乙酰基衍生物 13a-c 和 14a-c 和 N-苯甲酰基衍生物 15a-c 和 16a-c。
• Synthesis and structure–activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis
  作者：Emanuela Pesce、Marta Bellotti、Nara Liessi、Sara Guariento、Gianluca Damonte、Elena Cichero、Andrea Galatini、Annalisa Salis、Ambra Gianotti、Nicoletta Pedemonte、Olga Zegarra-Moran、Paola Fossa、Luis J.V. Galietta、Enrico Millo

  DOI：10.1016/j.ejmech.2015.05.030

  日期：2015.6

  targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide

  囊性纤维化跨膜电导调节剂 (CFTR) 是存在于上皮细胞膜中的氯离子通道。影响CFTR的突变基因导致囊性纤维化（CF），一种多器官严重疾病。最常见的 CF 突变 F508del 会损害 CFTR 蛋白的加工和活性（门控）。其他突变，如 G551D，只会导致门控缺陷。加工和门控缺陷可以分别被称为一般校正剂和增强剂的小分子作为目标。氨基芳基噻唑 (AAT) 代表了一类有趣的化合物，包括具有双重活性的分子，作为校正剂和增强剂。为了改善 AAT 的活性特征，我们现在设计并合成了一个新化合物库，以建立一个初始 SAR，该 SAR 可以提供有关对救援活动有益或有害的化学基团的指示。使用功能测定法在表达 CFBE41o 的 F508del-CFTR 中测试了新化合物作为校正剂和增强剂。双重活性化合物 AAT-如图 4a 所示，当与校正剂 VX-809 组合时，其特征在于提高的功效和显着的协同作用。此外，通过计算方法，已检测到核苷酸结合域
• Physiochemical Tuning of Potent<i>Escherichia coli</i>Anti-Adhesives by Microencapsulation and Methylene Homologation
  作者：Dimitri Alvarez Dorta、Thibaut Chalopin、Adeline Sivignon、Jérôme de Ruyck、Tetiana I. Dumych、Rostyslav O. Bilyy、David Deniaud、Nicolas Barnich、Julie Bouckaert、Sébastien G. Gouin

  DOI：10.1002/cmdc.201700061

  日期：2017.6.21

  trapped water molecule, and π-stacking with Tyr48 of FimH, respectively. Consequently, we developed NeoTazMan homologated with a methylene group for low-pH and mannosidase stability with a conserved NH group and bearing various heterocyclic aglycones. Microencapsulation of the lead NeoTazMan in γ-cyclodextrin dramatically improved water solubility without disrupting the affinity for FimH or the anti-adhesive

  噻唑基氨基甘露糖苷（TazMan）是FimH拮抗剂，具有对抗黏附性大肠杆菌（AIEC）促进克罗恩病患者肠道炎症的抗粘附能力。TazMan铅在体外具有很高的效力，但由于低pH稳定性和水溶性，其体内效率有限。我们最近开发了第二代稳定的TazMan，但抗粘连效果却低于第一代。在本文中，我们报道了FimH中的TazMan铅的共晶体结构，揭示了端粒的NH基团和第二噻唑部分与捕获的水分子提供了正的氢键相互作用，并与FimH的Tyr48形成了π堆积。所以，我们开发了与亚甲基同源的NeoTazMan，以降低pH和甘露糖苷酶的稳定性，并具有一个保守的NH基并带有各种杂环糖苷配基。领先的NeoTazMan微囊在γ-环糊精中的微囊化大大改善了水溶性，而不会破坏对FimH的亲和力或对克罗恩病患者分离出的AIEC的抗粘连作用。
• [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
  申请人：ENTEROME

  公开号：WO2017021549A1

  公开（公告）日：2017-02-09

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式(I)的甘露糖衍生物：其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基，Y代表单键、CH2、O、NR3、S，A代表O、NH或S，X代表H，X'代表OH或X和X'与它们相连的碳原子形成CO基团，R2代表H、线性或支链(C1-C6)-烷基或CF3，R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、CF3或COCF3，R如权利要求1中所述。式(I)的甘露糖衍生物对治疗与粘附性大肠埃希菌（AEC）存在相关的病理病变有用，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；尿路感染，特别是疼痛性膀胱综合征和膀胱炎，更特别是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症性疾病；以及结直肠癌，特别是结肠癌。